Sees FY23 revenue $8.58B-$8.73B, consensus $8.57B. Sees FY23 adjusted net income $2.49B-$2.54B. "Looking ahead, we are well-positioned with the strategy and capabilities to expand in large and growing product areas like parasiticides, dermatology products, monoclonal antibodies, vaccines and diagnostics, while still investing in comprehensive solutions across the continuum of animal care. We are committed to continuing our track record of value creation and above-market performance even in the face of today’s economic uncertainty, and we are guiding to full-year operational growth of 6% to 8% in revenue in 2023," said Peck.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ZTS:
